The estimated Net Worth of Kathy V Turner is at least $12 millió dollars as of 15 February 2023. Ms. Turner owns over 1,010 units of Idexx Laboratories stock worth over $3,617,629 and over the last 6 years she sold IDXX stock worth over $5,645,857. In addition, she makes $2,696,820 as Corporate Vice President and Chief Marketing Officer at Idexx Laboratories.
Kathy has made over 19 trades of the Idexx Laboratories stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 1,010 units of IDXX stock worth $515,191 on 15 February 2023.
The largest trade she's ever made was exercising 13,877 units of Idexx Laboratories stock on 10 November 2022 worth over $2,625,945. On average, Kathy trades about 2,661 units every 91 days since 2018. As of 15 February 2023 she still owns at least 7,379 units of Idexx Laboratories stock.
You can see the complete history of Ms. Turner stock trades at the bottom of the page.
Kathy V. Turner serves as Corporate Vice President and Chief Marketing Officer of the Company. Ms. Turner has been Corporate Vice President since May 2014 and leads the Company’s Europe, Middle East and Africa Companion Animal Commercial Operations, and the Company's Asia Pacific Companion Animal, Water, Livestock, Poultry and Dairy Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions with increasing responsibilities at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to May 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
As the Corporate Vice President and Chief Marketing Officer of Idexx Laboratories, the total compensation of Kathy Turner at Idexx Laboratories is $2,696,820. There are 3 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.
Kathy Turner is 56, she's been the Corporate Vice President and Chief Marketing Officer of Idexx Laboratories since 2020. There are 16 older and 7 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.
Kathy's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers és Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: